X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6862) 6862
Book Review (2298) 2298
Publication (659) 659
Book Chapter (56) 56
Conference Proceeding (55) 55
Dissertation (9) 9
Book / eBook (4) 4
Streaming Video (3) 3
Web Resource (3) 3
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4217) 4217
immunotherapy (3422) 3422
humans (3175) 3175
cancer (2932) 2932
oncology (2881) 2881
immune checkpoint (2057) 2057
tumors (1641) 1641
animals (1371) 1371
melanoma (1368) 1368
immunology (1338) 1338
apoptosis (1330) 1330
lymphocytes (1182) 1182
chemotherapy (1033) 1033
care and treatment (995) 995
nivolumab (987) 987
lymphocytes t (978) 978
metastasis (962) 962
female (933) 933
expression (901) 901
pd-1 (898) 898
checkpoint blockade (869) 869
t cells (848) 848
patients (829) 829
cancer therapies (803) 803
ipilimumab (788) 788
cell line, tumor (781) 781
cell biology (778) 778
therapy (733) 733
mice (726) 726
research (721) 721
antigens (707) 707
male (695) 695
immune checkpoint blockade (691) 691
pd-1 protein (688) 688
pembrolizumab (670) 670
lung cancer (657) 657
pd-l1 (656) 656
cytotoxicity (645) 645
analysis (640) 640
blockade (640) 640
pd-1 blockade (640) 640
review (628) 628
clinical trials (623) 623
proteins (607) 607
immunotherapy - methods (604) 604
health aspects (593) 593
metastases (584) 584
t-cells (584) 584
pd-l1 protein (574) 574
cell death (571) 571
immune response (564) 564
open-label (559) 559
gene expression (552) 552
survival (547) 547
immune checkpoint inhibitors (545) 545
cell cycle (525) 525
article (504) 504
mutation (503) 503
ligands (501) 501
medical research (501) 501
dendritic cells (499) 499
biochemistry & molecular biology (496) 496
tumor microenvironment (495) 495
checkpoint inhibitors (490) 490
medicine & public health (487) 487
biomarkers (484) 484
metastatic melanoma (483) 483
neoplasms - immunology (472) 472
activation (467) 467
drug therapy (462) 462
immune system (462) 462
middle aged (454) 454
kinases (432) 432
medicine, research & experimental (429) 429
antibodies, monoclonal - therapeutic use (418) 418
programmed cell death 1 receptor - antagonists & inhibitors (411) 411
apoptosis - drug effects (407) 407
cell cycle checkpoints - drug effects (405) 405
aged (403) 403
regulatory t-cells (392) 392
prognosis (390) 390
multidisciplinary sciences (388) 388
pharmacology & pharmacy (388) 388
immunity (387) 387
medical prognosis (387) 387
tumor-infiltrating lymphocytes (384) 384
signal transduction (383) 383
neoplasms - therapy (382) 382
cell lung-cancer (380) 380
genetic aspects (379) 379
antibodies (371) 371
cell proliferation - drug effects (371) 371
ctla-4 (371) 371
development and progression (359) 359
safety (359) 359
breast cancer (356) 356
antineoplastic agents - therapeutic use (354) 354
usage (354) 354
cd8 antigen (353) 353
cancer immunotherapy (338) 338
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6794) 6794
German (63) 63
French (36) 36
Japanese (14) 14
Korean (5) 5
Chinese (4) 4
Russian (2) 2
Spanish (2) 2
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Investigation, ISSN 0021-9738, 08/2017, Volume 127, Issue 8, pp. 2930 - 2940
Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies... 
CELL LUNG-CANCER | MEDICINE, RESEARCH & EXPERIMENTAL | MELANOMA | PEMBROLIZUMAB | LIGANDS | IMMUNOTHERAPY | SAFETY | TOLERANCE | ADAPTIVE IMMUNE RESISTANCE | EXPRESSION | Immunohistochemistry | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Tumor Microenvironment | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Interferon-gamma - metabolism | Immune System | Carcinoma - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Signal Transduction | Skin Neoplasms - immunology | Carcinoma - immunology | Programmed Cell Death 1 Receptor - metabolism | Treatment Outcome | Stomach Neoplasms - drug therapy | Stomach Neoplasms - immunology | Carcinoma, Non-Small-Cell Lung - immunology | B7-H1 Antigen - metabolism | Lung Neoplasms - immunology | Pilot Projects | Sequence Analysis, RNA | Biopsy | Melanoma - immunology | Melanoma - drug therapy | ROC Curve | Carcinoma, Non-Small-Cell Lung - drug therapy | PD-1 protein | Lung cancer | Clinical trials | Cytotoxicity | Biology | Lymphocytes T | Cancer therapies | Metastases | Lymphocytes | Neck | Adaptation | Antigen presentation | Squamous cell carcinoma | Cytokines | Melanoma | Inflammation | Gene expression | Immune checkpoint | PD-L1 protein | Head and neck cancer | Antitumor activity | Ligands | Interferon | Chemokines | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1749 - 1755
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 21, pp. 1976 - 1986
Journal Article
Science, ISSN 0036-8075, 10/2018, Volume 362, Issue 6411, pp. 197 - 197
Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) checkpoint blockade immunotherapy elicits durable antitumor effects in... 
CELL LUNG-CANCER | MISMATCH-REPAIR DEFICIENCY | MUTATIONAL PROCESSES | METASTATIC MELANOMA | CTLA-4 BLOCKADE | MULTIDISCIPLINARY SCIENCES | COPY NUMBER | PROGRAMMED DEATH LIGAND-1 | SEQUENCING DATA | CLINICAL-RESPONSE | SOMATIC MUTATIONS | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Transcriptome | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Genetic Markers | Cell Cycle Checkpoints | Neoplasms - therapy | Neoplasms - genetics | Antineoplastic Agents, Immunological - therapeutic use | Immunotherapy | Inflammation - genetics | T-Lymphocytes - immunology | Tumor Burden - genetics | Biomarkers, Tumor - genetics | Mutation | Molecular Targeted Therapy - methods | Monoclonal antibodies | Genetic aspects | T cells | Biological markers | Gene expression | Cancer | Tumors | Apoptosis | Cell receptors | Physiological aspects | Diagnosis | Identification and classification | Methods | PD-1 protein | Clinical trials | Genomes | Biology | Lymphocytes T | Microsatellite instability | Data bases | Subgroups | Anticancer properties | Proteins | Cell activation | Pembrolizumab | Databases | Antigenicity | Lymphocytes | Bioindicators | Deoxyribonucleic acid--DNA | Medical research | Stability | Microsatellites | Mortality | Melanoma | Data processing | Inflammation | Patients | Immune checkpoint | Cell death | Correlation analysis | PD-L1 protein | Biomarkers | Ligands | Antitumor activity | Cutoffs | Solid tumors | Index Medicus
Journal Article
Science, ISSN 0036-8075, 07/2017, Volume 357, Issue 6349, pp. 409 - 413
The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations. In a proof-of-concept study, we previously showed... 
CELL LUNG-CANCER | SURVIVAL | COLORECTAL CARCINOMAS | RECEIVING NIVOLUMAB | IMMUNOTHERAPY | MICROSATELLITE INSTABILITY | MULTIDISCIPLINARY SCIENCES | LONG-TERM SAFETY | NEOANTIGENS | CHECKPOINT BLOCKADE | LYMPHOCYTES | Neoplastic Syndromes, Hereditary - immunology | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Neoplastic Syndromes, Hereditary - mortality | Young Adult | Colorectal Neoplasms - therapy | Brain Neoplasms - immunology | DNA Mismatch Repair | Aged, 80 and over | Adult | Female | Neoplastic Syndromes, Hereditary - genetics | Brain Neoplasms - mortality | Biomarkers, Tumor - antagonists & inhibitors | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - therapeutic use | Antigens, Neoplasm - immunology | Brain Neoplasms - genetics | Disease-Free Survival | Colorectal Neoplasms - immunology | Cell Cycle Checkpoints - drug effects | Brain Neoplasms - therapy | Neoplastic Syndromes, Hereditary - therapy | T-Lymphocytes - immunology | Aged | Mutation | Programmed Cell Death 1 Receptor - immunology | Colorectal cancer | Genetic aspects | Nucleotide sequencing | Health aspects | DNA repair | Methods | Tumors | DNA sequencing | Yeast | PD-1 protein | Antibodies | Clinical trials | Genomes | Functional analysis | Lymphocytes T | Patients | Survival | Colon cancer | Immune checkpoint | Immunotherapy | Mismatch repair | Pancreatic cancer | Biomarkers | Bioindicators | Colon | Solid tumors | Genetic recombination | Repair | Cancer | Apoptosis | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 02/2018, Volume 554, Issue 7693, pp. 544 - 548
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients... 
METASTATIC MELANOMA | CTLA-4 BLOCKADE | BLADDER-CANCER | THERAPY | LANDSCAPE | SUBTYPES | UROTHELIAL CARCINOMA | MULTIDISCIPLINARY SCIENCES | GENES | ADAPTIVE IMMUNE RESISTANCE | MPDL3280A | CD8-Positive T-Lymphocytes - cytology | Humans | Antibodies, Monoclonal - therapeutic use | Urothelium - pathology | Urologic Neoplasms - pathology | Neoplasm Metastasis | Urologic Neoplasms - drug therapy | Urologic Neoplasms - genetics | Immunotherapy | Antibodies - immunology | Antigens, Neoplasm - metabolism | Transforming Growth Factor beta - antagonists & inhibitors | Antigens, Neoplasm - analysis | Disease Models, Animal | Fibroblasts - metabolism | Antibodies - therapeutic use | Antigens, Neoplasm - immunology | Antibodies, Monoclonal - pharmacology | Treatment Outcome | B7-H1 Antigen - immunology | Urologic Neoplasms - immunology | Antibodies - pharmacology | Tumor Microenvironment - immunology | Collagen - metabolism | Phenotype | Animals | B7-H1 Antigen - antagonists & inhibitors | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | CD8-Positive T-Lymphocytes - drug effects | Urothelium - immunology | Mice | Mutation | CD8-Positive T-Lymphocytes - immunology | Urothelium - drug effects | Transforming Growth Factor beta - metabolism | Cohort Studies | Drug Resistance, Neoplasm - drug effects | PD-1 protein | CD8 antigen | Transforming growth factor-a | Antibodies | Parenchyma | Lymphocytes T | Metastasis | Immunity | Metastases | Genotype & phenotype | Signal transduction | Lymphocytes | Cell cycle | Fibroblasts | Growth factors | Urothelial cancer | Phenotypes | Cytokines | Melanoma | Blocking | Gene expression | Patients | Generalized linear models | Signaling | Stromal cells | Medical prognosis | Collagen | PD-L1 protein | Ligands | Determinants | Infiltration | Cancer | Tumors | Apoptosis | Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Nature, ISSN 0028-0836, 2016, Volume 539, Issue 7629, pp. 443 - 447
Journal Article
Journal Article
The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 11/2018, Volume 142, Issue 5, pp. 1403 - 1414
Journal Article